FDA snow day delays review of Sarepta’s Duchenne drug

John Carroll FierceBiotech News

J&J halts a depression program in the shadow of fatal French trial

Damian Garde In the wake of a disastrous French clinical trial that left one volunteer dead, Johnson & Johnson has voluntarily suspended development of a similar drug until more ...

Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Tracy Staton Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use. FiercePharma News

Now focused on integrating Allergan generics, Teva eyes ‘much larger’ specialty buy in 2017

Carly Helfand SAN FRANCISCO–After watching months of pharma's M&A wave from the sidelines, Teva finally made a splash this summer with an agreement to pick up Allergan's ...

Want the skinny from the J.P. Morgan Healthcare Conference? We’ve got you covered

Carly Helfand SAN FRANCISCO–Sometimes, it can tough to be filter out what a company means from the little it says at the J.P. Morgan Healthcare Conference. So please, allow us ...

Iconic Therapeutics snags $40M for eye disease R&D

Damian Garde South San Francisco's Iconic Therapeutics raised $ 40 million in Series C cash to support its work on treatments for eye cancer, moving toward clinical trials with ...

What public outcry? New year brings dozens of double-digit drug price hikes

Tracy Staton All eyes may be on rising drug costs, but that doesn't mean pharma companies are backing away from price hikes. In recent days, analysts have spotlighted hundreds of ...

Roche and AbbVie line up for quick approval for cancer drug venetoclax

Damian Garde Partners Roche and AbbVie are speeding toward FDA approval with a cancer treatment tabbed as a potential blockbuster, picking up a priority review for a blood cancer therapy. FierceBiotech ...

German generics maker mulls $1.1B sale amid pharma’s M&A frenzy: Reuters

Emily Wasserman It's been a banner year for pharma M&A, and German generics maker Dermapharm is wise to the trend. The company is planning a €1 billion ($ 1.1 billion) ...

Shire inches closer to Baxalta buy with cash-sweetened bid

Carly Helfand Shire has offered up a new bid for elusive target Baxalta that's more or less what the Illinois drugmaker has been looking for, reports say. But that doesn't ...

Chimerix shares crash as antiviral flops and deaths spike in first PhIII challenge

John Carroll High hopes for Chimerix's antiviral turned into a bad case of data shock Monday morning after the biotech revealed that brincidofovir had failed its first Phase III ...

Nasdaq moves to delist KaloBios in wake of Shkreli bust

John Carroll Just days after kicking Martin Shkreli out as CEO, KaloBios says that Nasdaq plans to delist the company, citing the exec's arrest on fraud and looting charges as one ...
Page 2 of 5012345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS